Pertussis
177
6
8
141
Key Insights
Highlights
Success Rate
99% trial completion (above average)
Published Results
63 trials with published results (36%)
Research Maturity
141 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
1.1%
2 terminated out of 177 trials
98.6%
+12.1% vs benchmark
53%
94 trials in Phase 3/4
45%
63 of 141 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 141 completed trials
Clinical Trials (177)
Establishing a Controlled Human Infection Model of Bordetella Pertussis
Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Maternal Determinants of Infant Immunity to Pertussis
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents
Confirmatory Study of BK1310 in Healthy Infants
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
10-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
Pertussis Immunization During Pregnancy & HIV Infection
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine